Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Circulating Tumor Cells Clear all
Completed No phase listed Observational

Concordance Between ctDNA Assay and FoundationOne

NCT02620527
View directory record Official record
Conditions
Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing, Genomic Alterations
Interventions
Not listed
Lead sponsor
Foundation Medicine
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 3, 2026, 2:18 PM EDT
Not listed Phase 2 Interventional

Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

NCT01565837
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Stereotactic Ablative Radiosurgery (SART)
Drug · Radiation
Lead sponsor
Wolfram Samlowski
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 3, 2026, 2:18 PM EDT
Active, not recruiting No phase listed Observational

Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer

NCT04574635
View directory record Official record
Conditions
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma, Stage I Cervical Cancer FIGO 2018, Stage IA Cervical Cancer FIGO 2018, Stage IA1 Cervical Cancer FIGO 2018, Stage IA2 Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IV Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018, Stage IVB Cervical Cancer FIGO 2018
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 3, 2026, 2:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

NCT01830426
View directory record Official record
Conditions
Primary Lung Cancer
Interventions
Not listed
Lead sponsor
Epic Sciences
Industry
Eligibility
19 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
La Jolla, California • New Haven, Connecticut • Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 3, 2026, 2:18 PM EDT
Recruiting No phase listed Observational

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

NCT02586389
View directory record Official record
Conditions
Non-hematologic Cancer
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 3, 2026, 2:18 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Circulating Cell-free Genome Atlas Study

NCT02889978
View directory record Official record
Conditions
Neoplasms, Cancer
Interventions
Not listed
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
20 Years and older
Enrollment
15,254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
139
States / cities
Daphne, Alabama • Mobile, Alabama • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 3, 2026, 2:18 PM EDT
Completed No phase listed Observational

Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer

NCT00897338
View directory record Official record
Conditions
Breast Cancer
Interventions
flow cytometry, fluorescence activated cell sorting, immunohistochemistry staining method, immunologic technique, biomarker analysis
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 3, 2026, 2:18 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

NCT07224750
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer (GC), Colorectal Cancer Screening
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

NCT06828991
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions
Mosunetuzumab, ClonoSEQ
Drug · Device
Lead sponsor
Danielle Wallace
Other
Eligibility
70 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 3, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

NCT02080650
View directory record Official record
Conditions
Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Advanced MET Amplified Solid Tumor
Interventions
Mesenchymal-marker based ferrofluid (c-MET), Epithelial cell adhesion molecule (EpCAM) ferrofluid
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 3, 2026, 2:18 PM EDT
Active, not recruiting No phase listed Observational

Plasma 5hmC Signatures as a Marker of Colorectal / Appendiceal Peritoneal Metastasis

NCT04157322
View directory record Official record
Conditions
Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
Interventions
prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 3, 2026, 2:18 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

NCT03213041
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer

NCT02874885
View directory record Official record
Conditions
Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Rectosigmoid Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Recurrent Rectosigmoid Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
Interventions
Biospecimen Collection
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Not yet recruiting Phase 2 Interventional

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

NCT07513324
View directory record Official record
Conditions
HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions
Pembroluzimab, Observation
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Recruiting No phase listed Observational

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

NCT03655015
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Lung Tumor Resection
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Completed Not applicable Interventional

Abiraterone Acetate for Castrate Resistant Prostate Cancer

NCT01961843
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 3, 2026, 2:18 PM EDT
Recruiting No phase listed Observational

Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC

NCT04564989
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Completed No phase listed Observational

Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction

NCT00588510
View directory record Official record
Conditions
Osteosarcoma
Interventions
Blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Sep 3, 2026, 2:18 PM EDT
Completed No phase listed Observational Results available

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

NCT02135679
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Radiotherapy
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 3, 2026, 2:18 PM EDT
Recruiting Phase 2 Interventional

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

NCT05715229
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 3, 2026, 2:18 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

NCT05127096
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
FirstSight blood test
Diagnostic Test
Lead sponsor
CellMax Life
Industry
Eligibility
45 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
15
States / cities
Huntsville, Alabama • Chula Vista, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 3, 2026, 2:18 PM EDT
Terminated Phase 2 Interventional Results available

Genistein in Treating Patients With Prostate Cancer

NCT01126879
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions
genistein, placebo, therapeutic conventional surgery
Dietary Supplement · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 3, 2026, 2:18 PM EDT
Completed No phase listed Observational

Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)

NCT01716065
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Defense and Veterans Center for Integrative Pain Management
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Sep 3, 2026, 2:18 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.

NCT02036216
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Not listed
Lead sponsor
Peking Union Medical College Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 3, 2026, 2:18 PM EDT